You're asking about **1-[1-[(4-hydroxy-1-piperidinyl)-oxomethyl]cyclohexyl]-3-(2-methoxyphenyl)urea**. This is a complex chemical name, and I can provide some information about it, but without more context, it's difficult to say exactly what it's used for or its significance in research.
**Here's a breakdown:**
* **Structure:** The name indicates a molecule with several specific functional groups and a complex arrangement of atoms. It's likely a **heterocyclic** compound (contains atoms other than carbon in its rings) with a piperidine ring, a cyclohexane ring, a urea group, and a 2-methoxyphenyl group.
* **Potential Function:**
* **Piperidine and Cyclohexane Rings:** These are common structural features in molecules that interact with biological systems. They can provide a scaffold for binding to proteins or enzymes.
* **Urea Group:** This is a common functional group that can be involved in hydrogen bonding, which is important for interactions with other molecules, including biological targets.
* **2-Methoxyphenyl Group:** This group can add additional lipophilicity (fat-soluble properties) to the molecule.
* **Hydroxy Group:** The presence of a hydroxy group suggests the molecule might be involved in reactions or binding events that require a hydroxyl functional group.
**Importance in Research:**
Given the structure, it's likely that this compound is a potential **drug candidate** or a **chemical probe** used for research. Here's why:
* **Target Interaction:** The complex structure suggests it might be designed to interact with a specific biological target, such as an enzyme, receptor, or protein.
* **Drug Development:** Researchers often synthesize and test a large number of compounds to find those that have desirable properties for drug development, including potency, selectivity, and pharmacokinetic properties.
* **Chemical Probes:** Some complex molecules are used as chemical probes to study biological pathways or mechanisms.
**To understand the specific importance of this compound, we'd need more information:**
* **What specific research area is it related to?** (e.g., oncology, neurology, immunology)
* **What is the intended target or purpose?** (e.g., inhibition of a specific enzyme, modulation of a receptor)
* **What are the known properties of the compound?** (e.g., potency, selectivity, bioavailability)
**If you can provide more context, I can give you a more detailed answer.**
ID Source | ID |
---|---|
PubMed CID | 652071 |
CHEMBL ID | 1460222 |
CHEBI ID | 121352 |
Synonym |
---|
smr000000439 |
1-[1-(4-hydroxy-piperidine-1-carbonyl)-cyclohexyl]-3-(2-methoxy-phenyl)-urea |
MLS000029964 |
CHEBI:121352 |
1-[1-(4-hydroxypiperidine-1-carbonyl)cyclohexyl]-3-(2-methoxyphenyl)urea |
HMS2330J15 |
CHEMBL1460222 |
Q27209888 |
1-[1-[(4-hydroxy-1-piperidinyl)-oxomethyl]cyclohexyl]-3-(2-methoxyphenyl)urea |
SR-01000331011-1 |
sr-01000331011 |
Class | Description |
---|---|
N-acyl-amino acid | A carboxamide resulting from the formal condensation of a carboxylic acid with the amino group of an amino acid. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 125.8920 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 0.0398 | 1.0000 | 10.4756 | 28.1838 | AID901 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |